World's Best Scientists 2026 revealed!
James E. Herndon

James E. Herndon

D-Index & Metrics

Medicine

D-Index
132
Citations
63935
World Ranking
2318
National Ranking
1311

Overview

James E. Herndon is affiliated with Duke University in the United States. Their research primarily focuses on Medicine, with significant contributions across Oncology, Pulmonary and Respiratory Medicine, Genetics, Radiology, Nuclear Medicine and Imaging, and Immunology.

The main research topics covered by Herndon include:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Lung Cancer Research Studies
  • Immunotherapy and Immune Responses
  • Cancer Research and Treatments
  • CAR-T cell therapy research
  • Cancer survivorship and care

Herndon's work has been published extensively in several prominent venues, with the most frequent including:

  • Neuro-Oncology
  • Neuro-Oncology Advances
  • Journal of Clinical Oncology
  • UNC Libraries
  • Neuro-Oncology Practice

Among recent notable publications are:

  • Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy, 2021, Nature Communications
  • Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma, 2020, Clinical Cancer Research
  • Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer, 2020, Circulation
  • Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial, 2021, Journal of Cachexia Sarcopenia and Muscle
  • Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial, 2023, The Lancet Child & Adolescent Health

Frequent collaborators include Annick Desjardins, Katherine B. Peters, David M. Ashley, Margaret Johnson, and Henry S. Friedman. The number of joint publications with these coauthors ranges from 37 to 44, reflecting ongoing research partnerships.

Best Publications

  • IDH1 and IDH2 Mutations in Gliomas

    Hai Yan;D. Williams Parsons;Genglin Jin;Roger McLendon

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial

    Robert O. Dillman;James Herndon;Stephen L. Seagren;Walter L. Eaton

  • Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell

  • Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

    Gary M. Strauss;James E. Herndon;Michael A. Maddaus;David W. Johnstone

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • Morbidity and Mortality of Major Pulmonary Resections in Patients With Early-Stage Lung Cancer: Initial Results of the Randomized, Prospective ACOSOG Z0030 Trial

    Mark S. Allen;Gail E. Darling;Taine T.V. Pechet;John D. Mitchell

  • Recurrent glioblastoma treated with recombinant poliovirus

    Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier

  • Video-Assisted Thoracic Surgery Lobectomy: Report of CALGB 39802—A Prospective, Multi-Institution Feasibility Study

    Scott J. Swanson;James E. Herndon;Thomas A. D'Amico;Todd L. Demmy

  • Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion

    Carolyn M Dresler;Jemi Olak;James E Herndon;William G Richards

  • Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial

    Lee Gravatt Wilke;Linda M. McCall;Katherine E. Posther;Pat W. Whitworth

  • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

    Peter E. Fecci;Duane A. Mitchell;John F. Whitesides;Weihua Xie

  • Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B

    James E. Herndon;Mark R. Green;A. Phillippe Chahinian;Joseph M. Corson

  • Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)

    Rogerio C. Lilenbaum;James E. Herndon;Marcy A. List;Chris Desch

  • Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B

    Everett E. Vokes;James E. Herndon;Michael J. Kelley;M. Giulia Cicchetti

  • Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study

    Alice B. Kornblith;James E. Herndon;Lewis R. Silverman;Erin P. Demakos

  • Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial

    Amy P Abernethy;Amy P Abernethy;Amy P Abernethy;Christine F McDonald;Peter A Frith;Katherine Clark

  • Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

    G. M. Strauss;J. Herndon;M. A. Maddaus;D. W. Johnstone

  • TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL

    Hai Yan;P.J. Killela;Z.J. Reitman;Y. Jiao

Frequent Co-Authors

Henry S. Friedman
Henry S. Friedman Duke University
John H. Sampson
John H. Sampson Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Darell D. Bigner
Darell D. Bigner Duke University
David A. Reardon
David A. Reardon Harvard University
James J. Vredenburgh
James J. Vredenburgh Yale School of Medicine
Roger E. McLendon
Roger E. McLendon Duke University
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh
Gary E. Archer
Gary E. Archer Duke University
Amy P. Abernethy
Amy P. Abernethy Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering alternative routes into the healthcare sector or looking to advance their careers, online programs offer flexible and accessible options. With rising demand for nurses and healthcare professionals, the range of online degree pathways has expanded significantly.

Affordability is a key consideration for many students. Prospective doctoral candidates might explore the cheapest phd nursing programs to reduce financial burden while reaching the highest academic levels in nursing.

Registered Nurses (RNs) seeking career advancement can benefit from rn to bsn online pathways, enabling them to earn a bachelor’s degree with flexible schedules and often lower costs.

For individuals who already hold a non-nursing bachelor’s degree but want to enter the field, options like msn direct entry programs online allow faster access to advanced nursing roles without starting from scratch.

Additionally, those looking for accessible entry points into nursing can find online bsn programs for non nurses, which are designed to remove admission barriers and accelerate entry into the profession.

Best Scientists Citing James E. Herndon

Trending Scientists

Recently Published Articles